CDA | Evidence Driven
CDA | Evidence Driven

Avastin (with capecitabine) for Metastatic Colorectal Cancer - Details

Details

Files
Generic Name:
Bevacizumab
Project Status:
Complete
Therapeutic Area:
Metastatic Colorectal Cancer
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Avastin (with capecitabine)
Project Line:
Reimbursement Review
Project Number:
PC0055-000
Performance Metric:
N/A — Predated performance metrics
Strength:
25 mg/mL
Tumour Type:
Gastrointestinal
Indications:
Metastatic Colorectal Cancer
Funding Request:
In combination with capecitabine, for the first-line treatment of advanced or metastatic colorectal cancer (CRC) for patients who are not suitable for oxaliplatin or irinotecan-based therapy
Review Status:
Complete
Sponsor:
Cancer Care Ontario Gastrointestinal Disease Site Group
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
Check-point meeting (target date):
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Bevacizumab (Avastin) Capecitabine mCRC - Final pERC Recommendation Final Recommendation July 21, 2015 View PDF
Bevacizumab (Avastin) Capecitabine mCRC - Final Clinical Guidance Report Guidance Reports July 21, 2015 View PDF
Bevacizumab (Avastin) Capecitabine - Final Economic Guidance Report Guidance Reports July 21, 2015 View PDF
Bevacizumab (Avastin) Capecitabine - Initial pERC Recommendation Initial Recommendation July 3, 2015 View PDF
Bevacizumab (Avastin) Capecitabine mCRC - PAG Feedback on Initial Recommendation Feedback July 21, 2015 View PDF
Bevacizumab (Avastin) Capecitabine mCRC - Manufacturer Feedback on Initial Recommendation Feedback July 21, 2015 View PDF
Bevacizumab (Avastin) Capecitabine mCRC – Patient Advocacy Group (CCAC) Feedback on Initial Recommendation Feedback July 21, 2015 View PDF
Bevacizumab (Avastin) Capecitabine mCRC – Patient Advocacy Group (CCAC) COI Declarations COI Declarations July 21, 2015 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : November 13, 2015